Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

First Wave Biopharma Inc (FWBI)

First Wave Biopharma Inc (FWBI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,724
  • Shares Outstanding, K 2,025
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,790 K
  • 60-Month Beta 1.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.44
Trade FWBI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -2.17
  • Number of Estimates 2
  • High Estimate -1.92
  • Low Estimate -2.43
  • Prior Year -36.40
  • Growth Rate Est. (year over year) +94.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.15 +3.81%
on 04/15/24
5.07 -35.50%
on 03/19/24
-1.47 (-31.01%)
since 03/15/24
3-Month
3.15 +3.81%
on 04/15/24
9.35 -65.03%
on 03/01/24
-0.78 (-19.26%)
since 01/12/24
52-Week
2.75 +18.91%
on 12/19/23
73.00 -95.52%
on 04/17/23
-49.53 (-93.81%)
since 04/14/23

Most Recent Stories

More News
First Wave BioPharma (NASDAQ: FWBI) Makes Significant Progress in Phase 2 SPAN Clinical Trial

Trial Enrollment Completed for Investigational Therapy of Exocrine Pancreatic Insufficiency First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company

FWBI : 3.27 (-1.51%)
Pre-Market Brief: Stocks Mostly Lower Amid Renewed Recession Fears, Weak China GDP Weighs

March S&P 500 futures (ESH23) are trending down -0.33% this morning after three major U.S. benchmark indices shook off early losses and closed higher on Friday as investors assessed the start of the U.S....

ESH23 : 3,957.05s (-0.09%)
JPM : 182.89 (+0.05%)
BAC : 35.95 (+0.45%)
WFC : 56.97 (+0.89%)
C : 58.56 (-1.88%)
MS : 86.99 (+0.93%)
GS : 400.88 (+2.92%)
CFG : 33.00 (-0.42%)
BTBT : 1.88 (-8.74%)
MARA : 15.15 (-5.96%)
RIOT : 8.57 (-5.82%)
AN : 152.36 (-1.14%)
First Wave (FWBI) IND Filing Under FDA's Review, Stock Up

First Wave's (FWBI) stock gains as FDA reviews its IND amendment for the planned phase II study of an enhanced enteric microgranule delivery formulation of adrulipase.

INO : 10.99 (-0.36%)
SNDX : 21.62 (-0.46%)
FWBI : 3.27 (-1.51%)
ZyVersa Therapeutics Appoints Three New Board Members

/PRNewswire/ -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a clinical- stage specialty biopharmaceutical company developing first-in-class drugs...

ZVSA : 0.6355 (-10.49%)
FWBI : 3.27 (-1.51%)
Here's Why First Wave BioPharma, Inc. (FWBI) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for First Wave BioPharma, Inc. (FWBI), indicating that the stock has found support. This, combined with an upward trend in earnings...

FWBI : 3.27 (-1.51%)
First Wave BioPharma, Inc. Announces Private Placement

BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage...

FWBI : 3.27 (-1.51%)
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

BOCA RATON, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a...

FWBI : 3.27 (-1.51%)
First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio

Committee members include globally renowned experts in gastrointestinal diseases, including ulcerative colitis and Crohn’s disease...

FWBI : 3.27 (-1.51%)
First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

BOCA RATON, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a...

FWBI : 3.27 (-1.51%)
First Wave BioPharma to Participate in Maxim’s 2022 Virtual Growth Conference

BOCA RATON, Fla., March 22, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a...

FWBI : 3.27 (-1.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

First Wave BioPharma Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. First Wave BioPharma Inc., formerly known as AzurRx BioPharma Inc., is based in BOCA RATON, Fla.

See More

Key Turning Points

3rd Resistance Point 3.90
2nd Resistance Point 3.72
1st Resistance Point 3.50
Last Price 3.27
1st Support Level 3.10
2nd Support Level 2.92
3rd Support Level 2.70

See More

52-Week High 73.00
Fibonacci 61.8% 46.16
Fibonacci 50% 37.87
Fibonacci 38.2% 29.58
Last Price 3.27
52-Week Low 2.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar